<SEC-DOCUMENT>0001193125-23-269437.txt : 20231102
<SEC-HEADER>0001193125-23-269437.hdr.sgml : 20231102
<ACCEPTANCE-DATETIME>20231102164120
ACCESSION NUMBER:		0001193125-23-269437
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20231102
DATE AS OF CHANGE:		20231102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268117
		FILM NUMBER:		231373117

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d553370d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-268117 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated
November&nbsp;2, 2022) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to&nbsp;$250,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g553370g09c84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered
into a sales agreement, or the sales agreement, with Cowen and Company, LLC (TD Cowen), dated as of November&nbsp;5, 2019 and as amended on November&nbsp;2, 2022 and November&nbsp;2, 2023, relating to shares of our common stock offered by this
prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, as amended, we may offer and sell shares of our common stock having an aggregate offering price of up to $250,000,000 under this prospectus
supplement and the accompanying prospectus from time to time through TD Cowen acting as our agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the
Nasdaq Global Select Market (Nasdaq) under the symbol &#147;ALLO.&#148; On October&nbsp;31, 2023, the last reported sale price of our common stock was $2.82 per share.<B>&nbsp;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the sales agreement, TD Cowen may sell the common stock by any methods deemed to be an &#147;at the
market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the Securities Act). TD Cowen is not required to sell any specific amount of securities, but will act as our sales agent using commercially
reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between TD Cowen and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation to TD Cowen for sales of common stock sold pursuant to the sales agreement will be an amount up to 3.0% of the gross proceeds
of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, TD Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of TD
Cowen will be deemed to be underwriting commissions or discounts. We have agreed to reimburse TD Cowen for certain of its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. We have also agreed to
provide indemnification and contribution to TD Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the Exchange Act). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. You should carefully review the risks and uncertainties described under the
heading &#147;<A HREF="#suptx553370_3">Risk Factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-3</FONT> of this prospectus supplement and under similar headings in the other documents that are incorporated by reference into this
prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;2, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_7">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_8">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_9">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx553370_10">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement
<FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-3&nbsp;that</FONT> we filed with the Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148; registration process as a &#147;well-known seasoned issuer,&#148; as defined in Rule
405 under the Securities Act of 1933, as amended (the Securities Act). Effective as of the filing of this prospectus supplement, no further shares of common stock will be offered or sold pursuant to the $167,349,645 sales agreement prospectus
included in the registration statement (the initial sales agreement prospectus). As of immediately prior to the filing of this prospectus supplement, approximately $74.6&nbsp;million of common stock remained available for offer and sale pursuant to
the initial sales agreement prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to an offering of our common
stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the headings
&#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement. These documents contain important information that you should consider when making your investment
decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of
common stock and also adds to, updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is the accompanying prospectus, which gives more general information. Generally,
when we refer to this prospectus, we are referring to both parts of this document combined. To the extent the information contained in this prospectus supplement differs from or conflicts with the information contained in the accompanying prospectus
or any document incorporated by reference, the information in this prospectus supplement will control. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document
incorporated by reference into this prospectus supplement and the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and the sales agent has not, authorized anyone to provide you with information in addition to or different from that contained in
this prospectus supplement and the accompanying prospectus. We are not, and the sales agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information
appearing in this prospectus supplement and the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in
connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement and
the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety
before making an investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, references in this prospectus to the &#147;Company,&#148;
&#147;Allogene,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Allogene Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by
reference into this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete
understanding of our company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference in this
prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information under the heading &#147;Risk Factors&#148;
in this prospectus supplement beginning on page <FONT STYLE="white-space:nowrap">S-3</FONT> and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
immuno-oncology company pioneering the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy
donors for intended use in any patient, rather than from an individual patient for that patient&#146;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more
reliably, at greater scale, and to more patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in November 2017. Our principal executive offices are located at 210 East Grand Avenue, South San Francisco,
California 94080, and our telephone number is (650) <FONT STYLE="white-space:nowrap">457-2700.</FONT> Our corporate website address is www.allogene.com. Information contained on or accessible through our website is not a part of this prospectus
supplement or the accompanying prospectus, and the inclusion of our website address in this prospectus supplement or accompanying prospectus is an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus contains references to our trademarks and to trademarks belonging to other
entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols, but
such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#146; trade names or
trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $250,000,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>Up to 88,652,482 shares (as more fully described in the notes following this table), assuming sales of $250.0&nbsp;million of shares of our common stock in this offering at an offering price of $2.82 per share, which was the last reported sale
price of our common stock on Nasdaq on October&nbsp;31, 2023. The actual number of shares issued will vary depending on the sales price under this offering. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Manner of offering </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through our sales agent, TD Cowen. See &#147;Plan of Distribution.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We currently intend to use the net proceeds from this offering for general corporate purposes, including clinical trial expenses, research and development expenses, and general and administrative expenses. See &#147;Use of Proceeds.&#148;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-3</FONT><B></B>&nbsp;of this prospectus supplement, and under similar headings in other documents
incorporated by reference into this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;ALLO&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares to be outstanding after this offering is based on 168,175,221 shares of our
common stock outstanding as of September&nbsp;30, 2023, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21,989,462 shares of our common stock issuable upon the exercise of all stock options outstanding as of
September&nbsp;30, 2023, at a weighted-average exercise price of $10.37 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12,169,837 shares of our common stock issuable upon the vesting and settlement of all restricted stock units
outstanding as of September&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,730,462 shares of common stock reserved for future issuance under our 2018 equity incentive plan (2018 Plan) as
of September&nbsp;30, 2023, as well as any annual automatic increases in the number of shares of our common stock reserved for future issuance under the 2018 Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,469,951 shares of our common stock reserved for issuance under our 2018 employee stock purchase plan (ESPP) as
of September&nbsp;30, 2023, as well as any annual automatic increases in the number of shares of our common stock reserved for issuance under the ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully review the risks and uncertainties described below and
under the section titled &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022,&nbsp;as updated by our quarterly, annual and other reports and documents that we
have filed or subsequently file that are incorporated by reference into this prospectus supplement and the accompanying prospectus, before deciding whether to purchase any common stock in this offering. Each of the risk factors could adversely
affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our common stock, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional
risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Please also read carefully the section below titled &#147;Special Note Regarding Forward-Looking Statements.&#148;
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our common stock in this offering, you may experience immediate and substantial dilution in the net tangible book value of your
shares. In addition, we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to you. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of the shares we sell, as well as our existing stockholders, will experience significant dilution if we sell shares at prices
significantly below the price at which they invested. In addition, to the extent we need to raise additional capital in the future and we issue additional shares of common stock or securities convertible or exchangeable for our common stock, our
then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management might apply the net proceeds from this offering in ways with which you do not agree and in ways that may impair the value of your
investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering for general corporate purposes, including clinical
trial expenses, research and development expenses, general and administrative expenses, and capital expenditures. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> invest in or acquire businesses,
assets or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions. Pending the use of net proceeds, we intend to invest the net proceeds in
investment-grade, interest bearing instruments. Our management has broad discretion as to the use of these proceeds and you will be relying on the judgment of our management regarding the application of these proceeds. We might apply these proceeds
in ways with which you do not agree, or in ways that do not yield a favorable return. If our management applies these proceeds in a manner that does not yield a significant return, if any, on our investment of these net proceeds, it could compromise
our ability to pursue our growth strategy and adversely affect the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number of shares we will issue
under the sales agreement, at any one time or in total, is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sales agreement and
compliance with applicable law, we have the discretion to deliver a placement notice to TD Cowen at any time throughout the term of the sales agreement. The number of shares that are sold by TD Cowen after delivering a placement notice will
fluctuate based on the market price of the shares of common stock during the sales period and limits we set with TD Cowen. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales
period, it is not possible at this stage to predict the number of shares that will be ultimately issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The common stock offered hereby will be
sold in &#147;at the market offerings,&#148; and investors who purchase shares at different times will likely pay different prices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely pay different prices, and therefore may experience different
outcomes in their investment results. We will have discretion, subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market demand, to vary the timing, prices and number of shares sold. In addition, subject to any restrictions in any applicable placement notice delivered to TD Cowen, there is no minimum or
maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this prospectus supplement and the accompanying prospectus and in the documents incorporated by reference herein that
are not strictly historical in nature are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, and within the meaning of Section&nbsp;21E of the Exchange Act. These forward-looking statements are subject to the
&#147;safe harbor&#148; created by Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act and may include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost, timing and potential indications of our product development activities and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any planned investigational new drug application submissions to the U.S. Food and Drug
Administration for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, enrollment and completion of planned clinical trials in the United States and
foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for
which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding potential adverse consequences as a result of Les Laboratoires Servier SAS and
Institut de Recherches Internationales Servier SAS&#146;s (collectively, Servier) discontinuation of its involvement in the development of all CD19 products pursuant to our Exclusive License and Collaboration Agreement, including disagreements
relating to development cost contributions and the timeframe during which we have the right to elect a license to CD19 Products outside of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of
any of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to research, develop and commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain collaborators with development, regulatory and commercialization expertise;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with and the performance of our and our collaborators&#146; third-party suppliers and
manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and successfully operate our own manufacturing facility; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of cash and other resources, including our expected use of the proceeds from this offering; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product
candidates and our ability to operate our business without infringing on the intellectual property rights of others. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;goal,&#148; &#147;intends,&#148; &#147;may,&#148;
&#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; the negative of these words and words or similar expressions intended to identify forward-looking
statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying information and expectations are likely to change
over time. In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and
while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all
potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ
materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#147;Risk Factors&#148; in this prospectus supplement, the accompanying prospectus and the
documents incorporated by reference herein or any free writing prospectus that we authorize for use in connection with this offering. These forward-looking statements represent our estimates and assumptions only as of the date of the document
containing the applicable statement. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus supplement, the accompanying prospectus and in the
documents incorporated by reference herein by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you
should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our common stock in this offering, you should carefully consider the risk
factors discussed herein or incorporated by reference, in addition to the other information set forth in this prospectus supplement, the accompanying prospectus, any free writing prospectus we authorize for use in connection with this offering and
in the documents incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $250.0&nbsp;million from time to time. Because there
is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares
under or fully utilize the sales agreement with TD Cowen as a source of financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this
offering for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures. We may also use a portion of the net proceeds to <FONT
STYLE="white-space:nowrap">in-license,</FONT> invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions. As of
the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the net proceeds from this offering. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use of the net
proceeds from this offering, we intend to invest the net proceeds in investment-grade, interest-bearing instruments.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a sales agreement with TD Cowen, under which we may issue and sell from time to time under this prospectus supplement and
the accompanying prospectus up to $250,000,000 of our common stock through TD Cowen as our sales agent. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#147;at the market offering&#148; as
defined in Rule 415(a)(4) under the Securities Act, including sales made directly on Nasdaq or any other trading market for our common stock. If authorized by us in writing, TD Cowen may purchase shares of our common stock as principal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen will offer our common stock subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon
by us and TD Cowen. We will designate the maximum amount of common stock to be sold through TD Cowen on a daily basis or otherwise determine such maximum amount together with TD Cowen. Subject to the terms and conditions of the sales agreement, TD
Cowen will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct TD Cowen not to sell common stock if the sales cannot be effected at or above the price designated
by us in any such instruction. TD Cowen or we may suspend the offering of our common stock being made through TD Cowen under the sales agreement upon proper notice to the other party. TD Cowen and we each have the right, by giving written notice as
specified in the sales agreement, to terminate the sales agreement in each party&#146;s sole discretion at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate
compensation payable to TD Cowen as sales agent is up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. We also agreed to reimburse TD Cowen up to $50,000 of TD Cowen&#146;s actual outside legal expenses
incurred by TD Cowen in connection with offerings under the sales agreement, and for TD Cowen&#146;s FINRA counsel fees in an amount up to $10,000. We estimate that the total expenses of the offering payable by us, excluding commissions payable to
TD Cowen under the sales agreement, will be approximately $250,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining sales proceeds, after deducting any expenses payable by
us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen will provide written confirmation to us following the close of trading on Nasdaq on each day in which common stock is sold through it
as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the daily trading
volume and the net proceeds to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will report at least quarterly the number of shares of common stock sold through TD Cowen under the
sales agreement, the net proceeds to us and the compensation paid by us to TD Cowen in connection with the sales of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for sales of common stock will occur, unless the parties agree otherwise, on the second business day that is also a trading day
following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sales of our common stock on our behalf, TD Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of
the Securities Act, and the compensation paid to TD Cowen will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to TD Cowen against certain liabilities,
including liabilities under the Securities Act. As sales agent, TD Cowen will not engage in any transactions that stabilizes our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market and trades under the symbol &#147;ALLO.&#148; The transfer agent of our common
stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen and/or its affiliates have provided, and may in the future provide, various
investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_7"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common stock offered by this prospectus supplement will be passed upon by Cooley LLP, San Diego, California. Cowen and
Company, LLC is being represented in connection with this offering by Latham&nbsp;
&amp; Watkins LLP, Menlo Park, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2022, as set forth in their reports, which is incorporated
by reference in this prospectus supplement and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting
and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_9"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement we filed with the SEC. This prospectus
supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering
under this prospectus supplement and the accompanying prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized
any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date
other than the date on the front page of this prospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the securities offered by this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains
reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Allogene. The address of the SEC website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a website at www.allogene.com. Information contained in or accessible through our website does not constitute a part of this
prospectus supplement or the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx553370_10"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information that we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement and the accompanying prospectus. Information in this prospectus supplement and the accompanying
prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement and the accompanying prospectus, while information that we file later with the SEC will automatically update and
supersede the information in this prospectus supplement and the accompanying prospectus. We also incorporate by reference into this prospectus supplement and the accompanying prospectus the documents listed below and any future filings made by us
with the SEC (other than Current Reports or portions thereof furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items and other portions of documents
that are furnished, but not filed, and portions of documents that are otherwise not incorporated into registration statements, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of this prospectus supplement but prior to the termination of the offering of the common stock covered by this prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728723000018/allo-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on February&nbsp;28, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;
31, 2022 from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728723000041/allo-20230422.htm">Schedule 14A</A>, filed with the SEC on April&nbsp;24, 2023;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended
March&nbsp;31, 2023, June&nbsp;30, 2023 and September&nbsp;30, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728723000053/allo-20230331.htm">May&nbsp;
3, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728723000076/allo-20230630.htm">August&nbsp;
2, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728723000091/allo-20230930.htm">November&nbsp;2, 2023,</A> respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000003/allo-20221227.htm">January
<U></U>&nbsp;3, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000028/allo-20230418.htm">April<U></U>&nbsp;
20, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000056/allo-20230603.htm">June<U></U>&nbsp;
7, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000060/allo-20230609.htm">June<U></U>&nbsp;
14, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000063/allo-20230613.htm">June<U></U>&nbsp;
15, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000067/allo-20230615.htm">June<U></U>&nbsp;
21, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000079/allo-20231016.htm">October<U></U>&nbsp;
16, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001737287/000173728723000083/allo-20231016.htm">October<U></U>&nbsp;17, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock, which is registered under Section&nbsp;12 of the Exchange Act, in our
registration statement on Form <FONT STYLE="white-space:nowrap">8-A,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1737287/000119312518294785/d616804d8a12b.htm">October<U></U>&nbsp;5, 2018</A>, including all amendments
or reports filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial
owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement or the accompanying prospectus but not delivered with the
prospectus supplement or the accompanying prospectus, including exhibits which are specifically incorporated by reference into such documents. You should direct any requests for documents by writing us at 210 East Grand Avenue, South San Francisco,
California 94080, or by telephoning us at (650) <FONT STYLE="white-space:nowrap">457-2700.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a
document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed
document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g553370g53b65.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may offer and sell any combination of shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities in one or more offerings as described in this prospectus. We may also offer
securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will specify in an
accompanying prospectus supplement the terms of the securities being offered. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free
writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents
incorporated by reference, before you invest in any of the securities being offered. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This
prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
traded on the Nasdaq Global Select Market under the symbol &#147;ALLO.&#148; On October&nbsp;31, 2022, the last reported sale price of our common stock was $10.30 per share. The applicable prospectus supplement will contain information, where
applicable, as to any other listing on the Nasdaq Global Select Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a
continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &#147;Plan of Distribution&#148; in this prospectus. If any agents or underwriters are involved in the sale of any securities with
respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such
securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B><I>Investing
in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#tx553370_3">Risk Factors</A>&#148; contained in the applicable prospectus supplement and any
related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is&nbsp;November 2, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc1"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx553370_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of an automatic registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the
U.S. Securities and Exchange Commission (SEC) utilizing a &#147;shelf&#148; registration process as a &#147;well-known seasoned issuer,&#148; as defined in Rule 405 under the Securities Act of 1933, as amended (the Securities Act). Under this shelf
registration process, we may offer and sell from time to time in one or more offerings the securities described in this prospectus. No limit exists on the aggregate number or amount of securities we may sell pursuant to the registration statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this
prospectus, we will provide a prospectus supplement that will contain specific information about the terms of these securities and offerings. We may also authorize one or more free writing prospectuses to be provided to you that may contain material
information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that
we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under
the heading &#147;Incorporation of Certain Information by Reference,&#148; before investing in any of the securities offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIS
PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither we, nor
any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free
writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an
offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an
offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing
prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even
though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in
making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#147;Risk
Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the
information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, references in this prospectus to the &#147;Company,&#148; &#147;Allogene,&#148; &#147;we,&#148;
&#147;us&#148; and &#147;our&#148; refer to Allogene Therapeutics, Inc. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell therapies for the
treatment of cancer. We are developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells
are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#146;s use, as in the case of autologous T cells. We believe this key difference will enable us to
deliver readily available treatments faster, more reliably, at greater scale, and to more patients. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in November 2017. Our principal executive offices are located at 210 East Grand Avenue, South San Francisco,
California 94080, and our telephone number is <FONT STYLE="white-space:nowrap">(650)&nbsp;457-2700.</FONT> Our corporate website address is www.allogene.com. Information contained on or accessible through our website is not a part of this
prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus contains
references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do
not intend our use or display of other companies&#146; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Securities We May Offer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities, from
time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant
offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific
amounts, prices and other important terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">important U.S. federal income tax considerations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change
information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the
effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale
of securities unless it is accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors or through
underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the
applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those underwriters or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated net proceeds to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B><I>.</I> We may issue shares of our common stock from time to time. Holders of our common stock are entitled to one
vote per share for the election of directors and on all other matters that require stockholder approval. Subject to any preferential rights of any then outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders
of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding preferred stock. Our common stock does not carry any preemptive rights enabling a holder
to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock</I></B><I>. </I>We may issue shares of our preferred stock from time to time, in one or more series. Under our amended
and restated certificate of incorporation, our board of directors has the authority, without further action by stockholders, to designate up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences,
privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference and sinking fund terms, any or all of
which may be greater than the rights of the common stock. To date, none of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the 10,000,000 authorized shares of preferred stock have been designated by our board of directors. Convertible preferred stock will be convertible into our common stock or exchangeable for our
other securities. Conversion may be mandatory or at the option of the holders of our preferred stock and would be at prescribed conversion rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this
prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate of
designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you, however, to read the applicable prospectus supplement (and any related free writing
prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities</I></B><I>. </I>We may issue debt securities from time to time, in one or more series, as either senior or subordinated
debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and
in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into our common stock or preferred stock. Conversion may be mandatory or at the holder&#146;s option and
would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under one or more documents called indentures, which are
contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement
(and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of indenture has been
filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration
statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants</I></B><I>. </I>We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more
series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features
of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete
warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration
statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from
reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be
issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being
offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the
heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated
by our quarterly and other reports and documents that are incorporated by reference into this prospectus and the applicable prospectus supplement, before deciding whether to purchase any of the securities being registered pursuant to the
registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the
occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this prospectus, the applicable prospectus supplement and in the documents incorporated by reference herein and
therein that are not strictly historical in nature are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, and within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the
Exchange Act). These forward-looking statements are subject to the &#147;safe harbor&#148; created by Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act and may include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost, timing and potential indications of our product development activities and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any planned investigational new drug application submissions to the U.S. Food and Drug
Administration for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, enrollment and completion of planned clinical trials in the United States and
foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding potential adverse consequences as a result of&nbsp;Les Laboratoires Servier SAS and
Institut de Recherches Internationales Servier SAS&#146;s (collectively, Servier)&nbsp;discontinuation of its involvement in the development of all CD19 products pursuant to our&nbsp;Exclusive License and Collaboration Agreement, including
disagreements relating to development cost contributions and the timeframe during which we have the right to&nbsp;elect a license to CD19 Products outside of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for
which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of
any of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to research, develop and commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain collaborators with development, regulatory and commercialization expertise;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with and the performance of our and our collaborators&#146; third-party suppliers and
manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and successfully operate our own manufacturing facility; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of cash and other resources, including our expected use of the proceeds from any offering under this
prospectus; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product
candidates and our ability to operate our business without infringing on the intellectual property rights of others. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;goal,&#148; &#147;intends,&#148; &#147;may,&#148;
&#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; the negative of these words and words or similar expressions intended to identify forward-looking
statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying information and expectations are likely to change
over time. In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and
while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all
potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ
materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#147;Risk Factors&#148; in any applicable prospectus supplement, the documents incorporated
by reference therein or any free writing prospectus that we authorized. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Our actual future results may
be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement by these cautionary statements. Unless
required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing
out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully consider the risk factors discussed herein or incorporated by reference, in addition to the other information set forth
in this prospectus, any accompanying prospectus supplement or free writing prospectus and in the documents incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we
currently intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, and capital
expenditures. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although we have no current
plans, commitments or agreements with respect to any acquisitions. As of the date of this prospectus, we cannot specify with certainty all of the particular uses of the net proceeds from the sale of securities under this prospectus. Accordingly, we
will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from the sale of securities under this prospectus as described above, we intend to invest the net proceeds in investment-grade, interest-bearing
instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 400,000,000 shares of common stock, $0.001 par value, and 10,000,000 shares of preferred stock, $0.001 par value. All of our authorized preferred stock is undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary description of our capital stock is based on the provisions of our amended and restated certificate of incorporation and
amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law (DGCL). This information is qualified entirely by reference to the applicable provisions of our amended and restated certificate of incorporation,
amended and restated bylaws and the DGCL. For information on how to obtain copies of our amended and restated certificate of incorporation and amended and restated bylaws, which are exhibits to the registration statement of which this prospectus is
a part, see &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information Reference.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the
stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors
standing for election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Subject to preferences that may be applicable to any then-outstanding preferred stock, the
holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation, Dissolution or Winding Up</I>. In the event of our liquidation, dissolution or&nbsp;winding up,&nbsp;holders of our common
stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the
holders of any outstanding shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences</I>. Holders of our common stock have no preemptive,
conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the
rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fully Paid and
Nonassessable. </I>All of our outstanding shares of common stock are fully paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up
to&nbsp;10,000,000 shares of convertible preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly
unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series, as well as the qualifications,
limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that
series of preferred stock. This description will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate per share, dividend period, payment date or dates and method of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock or other securities of ours, including
warrants, and, if applicable, the conversion price, or how it will be calculated, and under what circumstances and the mechanism by which it may be adjusted, and the conversion period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities or other securities of ours, and, if
applicable, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuances of any class or series of preferred stock ranking senior to or on parity with the
series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, rights, preferences, privileges, qualifications or limitations of, or restrictions on
the preferred stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue shares of preferred stock under this prospectus, the shares will be fully-paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides that the holders of preferred stock will have the right to vote
separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change the powers, preferences or special rights of the class or series
so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current
plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Bylaws
and Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the DGCL, which generally prohibits a public Delaware corporation from engaging in a &#147;business
combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon
consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee
participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to the consummation of the transaction, the business combination is approved by the board and
authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets
of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 of the DGCL defines an
interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions
involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in
their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences
and privileges as they may designate (including the right to approve an acquisition or other change in our control); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the board of directors or any individual director may only be removed with cause and the affirmative
vote of the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of our then outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be
filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divide our board of directors into three classes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief
Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that to the fullest extent permitted by law the Court of Chancery of the State of Delaware will be the
sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii)&nbsp;any
action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws, and (iv)&nbsp;any action asserting a claim against us governed by the internal affairs
doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and registrar&#146;s address is 6201 15th Avenue, Brooklyn, NY 11219. The transfer agent for any series of preferred stock
that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the Nasdaq Global Select
Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;ALLO.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended (the Trust Indenture Act). We have filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue
discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be
described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of
the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any, and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will
set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or
exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of
debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a
subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the
Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following
are events of default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice
of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is
continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us,
the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;Description of Debt Securities-Consolidation, Merger or
Sale;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;Description of Debt Securities-General&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights
of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be
deposited with, or on behalf of, The Depository Trust Company (DTC), or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in
global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any
registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will name in the
applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the
designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange of any debt securities so selected for redemption, in whole or in part,
except the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and
liabilities that it might incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing
prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series.
Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will
apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing
prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security
that is not registered and described in this prospectus at the time of its effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements
as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the
form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are
subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the
applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the
terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We
will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to force the exercise of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the
laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal
holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names as &#147;indirect holders&#148; of those securities. As we discuss below, indirect
holders are not legal holders and investors in securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may
be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These
participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in
the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes
along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their
customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As a result, investors in a global security will not own
securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A global security may be terminated in certain situations as described under &#147;-Special Situations When a Global Security Will Be
Terminated,&#148; or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be
registered in the name of a bank, broker or other financial institution that the investor chooses, and&nbsp;the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other
financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they
receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not
holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders
of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or
has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further
responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval
of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal
holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented
by one or more global securities or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, the DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A global
security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#147;-Special Situations
When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be
permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution
that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will
be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#146;s rights relating to a global security will be governed by the account rules of the investor&#146;s
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If securities are issued only as global securities, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in the global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule 415
under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of the Nasdaq Global Select Market or any other securities exchange or quotation or
trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through a market maker other than on the Nasdaq Global Select Market or such other securities exchanges or
quotation or trading services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Such &#147;at the market offerings&#148;, if any, may be conducted by underwriters
acting as principal or agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be
provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a
material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will
name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis
for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors
to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may provide agents and
underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these
liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Other than common stock, all securities we offer will be new issues of securities with no established trading market. Any underwriters may
make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves
sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve
purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are
purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any
time. These transactions may be effected on any exchange or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on the Nasdaq Global Select Market may engage in passive market making transactions in the
securities on the Nasdaq Global Select Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply
with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids
are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level
above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of
the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable
prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2021, as set forth in their reports, which is incorporated
by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and
auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and
schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer
is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities
offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC
maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Allogene. The address of the SEC website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We maintain a website at www.allogene.com. Information contained in or accessible through our website does not constitute a part of this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx553370_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information that we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We also incorporate by reference into this prospectus the documents listed below and
any future filings made by us with the SEC (other than Current Reports or portions thereof furnished under Item&nbsp;2.02 or Item&nbsp;7.01 <FONT STYLE="white-space:nowrap">of&nbsp;Form&nbsp;8-K&nbsp;and&nbsp;exhibits</FONT> filed on such form that
are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange
Act&nbsp;after the filing and concurrent effectiveness of the registration statement but prior to the termination of all offerings covered by this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000013/allo-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2021, filed with the SEC on February&nbsp;23, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1737287/000173728722000026/allo-20220414xdef14axdefin.htm">Schedule 14A</A>,
filed with the SEC on April&nbsp;26, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended
March&nbsp;31, 2022, June&nbsp;30, 2022 and September&nbsp;30, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000035/allo-20220331.htm">May<U></U>&nbsp;4,
2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000067/allo-20220630.htm">August<U></U>&nbsp;
9, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000083/allo-20220930.htm">November&nbsp;2, 2022</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000039/allo-20220615.htm">June
<U></U>&nbsp;17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000049/allo-20220708.htm">July<U></U>&nbsp;
12, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000072/allo-20220915.htm">September<U></U>&nbsp;
21, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1737287/000173728722000074/allo-20221006.htm">October<U></U>&nbsp;6, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock, which is registered under Section&nbsp;12 of the Exchange Act, in our
registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1737287/000119312518294785/d616804d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on October&nbsp;5, 2018, including all amendments or
reports filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial
owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are
specifically incorporated by reference into such documents. You should direct any requests for documents by writing us at 210 East Grand Avenue, South San Francisco, California 94080, or by telephoning us at (650)
<FONT STYLE="white-space:nowrap">457-2700.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be
incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be
incorporated by reference into this document modifies or supersedes the statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $250,000,000 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g553370g79m67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;2, 2023 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>d553370dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>424(b)(5) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Allogene Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered and Carry Forward Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Maximum<BR>Aggregate<BR>Offering<BR>Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Amount of<BR>Registration Fee<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees&nbsp;to&nbsp;be&nbsp;Paid&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Common&nbsp;stock,<BR>par&nbsp;value&nbsp;$0.001<BR>per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(r)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$250,000,000&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.00014760&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$36,900</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$250,000,000&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$36,900</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$11,499.98&nbsp;(2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$25,400.02&nbsp;(2)</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;). Payment of the registration fee at the time of filing of the registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268117)</FONT> on
November&nbsp;2, 2022 was deferred pursuant to Rules 456(b) and 457(r) under the Securities Act and is paid herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On November&nbsp;5, 2019, the registrant filed a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-234516)</FONT> (the &#147;2019 Registration Statement&#148;), registering, among other securities, the issuance of up to $250,000,000 of Common Stock of
the registrant in an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering of the registrant&#146;s Common Stock (the &#147;2019 ATM Common Stock&#148;). The registration fee associated with
the 2019 ATM Common Stock was $32,450. Pursuant to the 2019 Registration Statement, the registrant sold $82,650,355 of the 2019 ATM Common Stock, which equates to an associated registration fee of $10,728.02 based on the total registration fee paid
in connection with the filing of the 2019 Registration Statement. Accordingly, the unused registration fee paid in connection with the 2019 Registration Statement and the 2019 ATM Common Stock is $21,721 (the &#147;Unused 2019 Registration
Fee&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;2, 2022, the registrant filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268117)</FONT> (the &#147;2022 Registration Statement&#148;), registering, among other securities, the issuance of up to $167,349,645 of Common Stock of the
registrant in an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering of the registrant&#146;s Common Stock (the &#147;2022 ATM Common Stock&#148;). The registration fee associated with the
2022 ATM Common Stock was $18,441.93, offset in its entirety by the Unused 2019 Registration Fee. Pursuant to the 2022 Registration Statement, the registrant sold $92,749,645 of the 2022 ATM Common Stock, which equates to an associated registration
fee of $10,221.02 based on the total registration fee paid in connection with the filing of the 2022 Registration Statement. Accordingly, the unused registration fee paid in connection with the 2022 Registration Statement and the 2022 ATM Common
Stock is $8,220.91. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $250,000,000 of Common Stock
of the registrant being registered hereby in the amount of $36,900 is offset by (i) $3,279.07 in registration fees previously paid by the registrant with respect to the 2019 ATM Common Stock that were registered but not issued pursuant to the 2019
Registration Statement and not used to offset the registration fees previously paid by the registrant with respect to the 2022 ATM Common Stock that were registered pursuant to the 2022 Registration Statement and (ii) $8,220.91 in registration fees
previously paid by the registrant using the Unused 2019 Registration Fee with respect to the 2022 ATM Common Stock that were registered but not issued pursuant to the 2022 Registration Statement. Accordingly, $11,499.98 in registration fees are
being paid at this time. Concurrently with the filing of this registration statement, any offering of unsold 2022 ATM Common Stock pursuant to the 2022 Registration Statement is hereby terminated. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 2: Fee Offset Claims and Sources </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Registrant<BR>or Filer<BR>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Form&nbsp;or<BR>Filing</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>File<BR>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Initial<BR>Filing<BR>Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Filing<BR>Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Type<BR>Associated<BR>with Fee<BR>Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Title<BR>Associated<BR>with Fee<BR>Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Unsold<BR>Securities<BR>Associated<BR>with Fee<BR>Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Unsold<BR>Aggregate<BR>Offering<BR>Amount<BR>Associated<BR>with&nbsp;Fee<BR>Offset</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Claimed</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Fee&nbsp;Paid&nbsp;with<BR>Fee Offset<BR>Source</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="20" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="19" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Rule 457(p)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fee Offset</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Claims</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Allogene<BR>Therapeutics,<BR>Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">333-234516</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">11/5/2019</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$3,279.07 (1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Common Stock</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$167,349,645</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fee Offset Sources</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Allogene<BR>Therapeutics,<BR>Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">333-234516</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">11/5/2019</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$3,279.07</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fee Offset</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Claims</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Allogene<BR>Therapeutics,<BR>Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">333-268117</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">11/2/2022</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$8,220.91 (1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Common Stock</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$250,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Fee Offset Sources</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Allogene<BR>Therapeutics,<BR>Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">333-268117</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">11/2/2022</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$8,220.91</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note (2)&nbsp;under Table 1 above. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g553370g09c84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g553370g09c84.jpg
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M<8$:(R0V05%8=GB6H;49)3(U.#I787)UL;*TMK?5U__$ !T!  (" P$! 0
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MQ(G8<J\(J/'Y)WHY1V&LB&<*:)<K.Z@JXYHVLJPP9?M&,RM,S^E*>33( B(
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MH3N^W(-!,5#^SUY<T\N]P6^T]L3:,V97]MZ6%)$)%4J\L&&ZO:VP) ,![R;
M7^\7&2@D,("SC(XB-<DD&8^5*OVVR;EB.3;K?=/Z\O9[2PU/3)KJ@SJ-G[C;
M J(&\ 9,B! 4&$<I5!C')<R1#Y)Q=X_I;T_VB[VOR4YFYF;;*M;4%&8\56J1
MWEV*<.M4QA[T6E,K/DDQ>8AI>.V(K6Z*JMCXPZJ]G4M[!ZNA]^<Z$1M+PH!9
MLBB@]O6V\(9(RF.E4$:^CD.L95BDA9*\]$I;H9?N'DC4>I?;R)@Z&"FNS!TS
M9RC@:6#KW,6Z+&0,1,D@\3;9+PD;(8J-_ <,@0B9$>,SP*"*=XA3MMJ/N1J/
MN/D,#K.F>(TLMYU%Y&WCFIIX5,Y%2:S*MR8'\2K^F:ZRP :WR !6%&D-Q//\
M1=4V+WO0/8M?=>52#YEJT6*>PES/(FV-U()8B["9RD=,!+M_/GQ%BVET1RFS
M>E3&=]1JRQULC( #7ZZ:16),!DLGJVOE:62HL1!CZ19U@L TQ>#5L0,-EIDY
M B.\C$CL4":AC:"_0'O#HC0_T[YSMYJC0FJJ>9;7=_"&U4SEG$7:==N)M4+=
M/)./&+H)5BLLYSA &D#I*NUE6^TX(Z\\*5 \U^NSEBK8,XN'*51-SS(#$;"G
MAYF6_5$BM61OS8=NP?@&*0C[(L_+.%!6HIFB*:"$MB+QSLDD_*J-.#P)T*H8
MFB%FQ-4'M*&[2X1@R:XCC8!& DIB!@8V]AB)*?> .ZG==6L]0W.X&J'X7$3G
MG8JHJ<?!KQQGZ6O0QX(,VVFO-Z4 9V&.9!?>SDJN @N<OFSTO]'AT=5Z_P 0
MWU__  ,\QAN;HH4^VGG23Q="0X:K9U>"JBB[EJZD>RF4]OJ-OU><W$1E'57&
M$"@328-,9VRW4QJZZ)QGJL@=Y@[IH1$AO'L5ED3"_P"?QA!LG;]4_%,[;QU7
MWZA-7_@VF$Z<JMXW]2'(V.);&K$52 [,SM[CZM\IJQ$_:U'K!]^,QU7'5J&_
MO4_9G!?7)%%PHM9$1%W"B+326'80;N7Z[::U 954VVWT?DJJDL<_.=U4VZK-
MS,GK%-#ZX/=QN\1:I:DKYC&C,1X&E6Y;P6^PQ*K0?EQBPMG';?<5Q,S]_5=2
MP^?[4Y/0FK6B4ED:B\O"H&5\8EA#=Q#IG>88S%6:WFF8&0.X80.Z)*?Z#5=3
M^+6K 879L')I&8=8$6!3&,%$OAC5\"D0UL5&.-M,9VRDKNT=)?7;[Y^HW7PH
M@KC51/?7$+O2RLYM=PR#4L-3!G\C I$H_?&\>T_G'O'7Z 8Z_5RM"EDZ+8=3
MR%5%RJV/AB+*A:HMMYVF0..0S[B6XS[Q/42?9QKC;U[]BXS_ #8Y_L7;^O0$
MXVQ_MQCSI8#^.L7_ $U'^,XZ4NYD;]O]8;_W R,_X$%,?XXZ2+^%_P#[P^P?
M\[J<_P!S6%XV=P/ZOC/^2M?Y:>H4^F/^+]7_ -,Q'^8O]07J'&4_Q&A;&,Y_
M?KN[\_'^;]E8_/\ .V/Z/AOG7_OQYU[7]8P_\VU/\XGI&Q'M]13?[[<W_CKW
M]_\ OZN)]*=(U-R;3\INZZ)#^00N+HIZ?(W2U=FY":>9WT$1>,"\JH[%I":<
M:918L\*H())Z."))VP$,2!!I&-"C9R5E=2H'-K)GYG8 &/UF,+:>(!'N4[3/
MP(P12(S<#4FH\3I3$6LWF;'IZ56(C[8YNL./>$UJRMXEMAQ1Q -X&(@F,):@
M8P:M97W+^T/L^:GP_ O.ZD?AH%Q\N'(* ?PJ2ABV5VW^R5F\QDB&U= W)%)+
MZ[04F$8;I;_<-D"9K5##K,@CI?3^*4!YJ]!M./@G>G7,Q\PE2Y\YQ$SM)<I_
M*>(;[=5>;WD[GZRNV$Z"T[->F@MN2:'XI:6,[\"NW+,?AR"9$<@5" F)Y##7
M0//K-5Y[QNZ^3[-$5Q['N>GJP(ELFJZ+I01Q5]F-A>RVJ+B0QUOE1O7T^%,\
MYSK]D,9A4W+C"B/ZH04T^AYY?I+$9*N3\%>CF/P$NBQ7DOF%G.TO04_M.3F(
M]_'/SUFQ_>_7.E,FG&]QM/'*&;23HHEC,F*N4"5BN.XX_(*#XX*!$$6\>JB8
MX]6KZHM6 7A7,/MFK9*PE\ G89N=C,A'94P@^8KYW3W3507T2=,2#%TDX'E1
M;Y%N1$DVCP:1;-GK5=!..[-9U1[:UA<J<DY!@%\Q,>_M,>TB43!"43(D,P0S
M,3$]6HQ65H9O'5,MB[*[E"\D7UK"YGB8%O$Q,3$$# *"6U1P+%- UL$3$AA1
M/M(]R,)X/?Z5!6D<%6IT:_%MRKP,5>.$8368TBCA<0]G.XQ9 H3,%F^R;X9#
MACP4\4$*I&29D0T=A4S;+I[2[<Q'J7F5>B)2,&,1+;!#.Q0GE$B(C,2)-*"B
M"^T1*8+C$G=#O%2T(<8C&UU974;%"TTM,AI8Q3!Y)9>E4PUKFQ(FJFLU'*9A
MS7) TPY340[F_$+3<4A=,5I62'*X=):FA\<3YTCR 0R)WQAPBH#%KLVEJ'1+
MM#.-F;P*8>JO6^VBK-\MG?57+&W$:*27I66P%\?:3/7')B7Q]Y1,UP*)^8(8
M@9_6B/?J**FN/J"NI'-5<)8?C2CS+K1IZN*7)G[HE"B$,J]1#,2!I<<F/N!E
M\]:[T/\ B&>EB<$J'6I@(&D[G"D+(C?1,)/0U*3",E ^\+UAQJ,?JI'8L!:O
M55YFR)1HDJX+A2(Q1H_=D$=&!%WDHZ*H"ZUZDSMU#&NRBX&RLN)>7R@SQ["<
MQLJ18.PD)1(P,R0QK:A^H/4C*.(C$UT87-)9D:VHJ5BG%E/E3Z**;ZOJH\R!
M.2N@VLV2<EBI R8, P[:'/5@%)WS=1UISA^P3-3*D*TL"7E/D;"A>A210,+(
MY _^GC*;0:PU=O';CY,;:-F;?'R_'5)/XXC>Z@4W[=9,%(*MV$*'W(I%;C6$
M?M(MHB/VS/5L-/7VW].83*76+A]S"8V_;;L*E0VQ018L,V]@6N#,RVW@0'V]
MHCJN+U=[ZK>G]N..?O6I5>+&)Y).PC&RG42,SZ0S1\SRIJZ>UG7HK.B2(%ME
M'=PC(Y0B8U(COJ/58\&:I:/%WG':.K)K1=SUGP#Q@RKPP$@J)^(L/+>9.=XB
M07(2)?;S*9VBN>JN_&7R&6+3_;;%?B+?*:%Y(JCK]BZ83/,\;CU;1"!X\HL6
MA=#%[G-=(1!S'\[['/>UR*FSLOINH7DDK#=TVP3S/J6C J+,4':VB2;-W+JA
M:1]:*D7.=_H#-I*^6SEYG37<<0SKNU4W P>D,E,U\?:A=C:>/AM,)DS'YPNS
M)PR(^2A<1[?!#\]<!_<;OII* R6IL0=G&20>7U^&JJJ@)S$0!V\0%<JK"WXK
MFR<_?,1*V;2$V+/7S[#:?]@]6/)I D',3G4258C[-JTP]0?&H:2()+;L'C5^
MBDV3/14U]J]R!D*3-CEWLR>-'PX829N6221FL):PMB%.F&);$E7L!$P#1&8B
M8D9F9!@;QS"9G;>)$B&8F;$=O^X6'[@8L[M 2J7JD@O)XMQB;Z;&04K,6# Q
M8JNX'X+$ '/@8,6IH$$*2]V?LQZXXHZ+K&NN?YC'(W%912@Z:%FQB#QF3N5I
M"O.IP#7<)/#;!VN@CD:$&I8:I[80UWTW5UUPHKOMEDTG@<;EJ5A]U1L8NU*A
MD7,7'#PJ/:8 HB9Y%,[_ #^7QU$W>KN7JW16HL9CL!<K5ZMK"KNN%U*M:.;!
M7KR)*#<!D(^-"XXQ]N\3,>\SU@[]]O/:71MJR>C_ %84L]G@R *:BY?>"<-3
MF6Q(PCMNU</P>#&Z5=Q&*.'[=ZB$(S#!1W*T6^I :W%-\9;K9*>F<51K!;U#
M;%!.^Y53R^+B$^\"?'=S61$Q)BKC"Y^TI*?>,.?[N:TU%E;6#[6X4[Z\?/BM
MYN*<7/(X=Q(T>;;'5*I,$Q0RY+3M0/D6*Q^THHB?<=[3>);9C\7[ZJ]65QDU
MOJZ?!977D:KB4OH_HX30(%:VF$!'AH6:<C=U-=5=73&0CE5L8&NG0E=QH_;=
M M+Z>RU9C,-8\; ]A);V/6)[;B#U.DFA!?E,$!;?=$'$2,JB>\/='1.6KU=?
M8N;=5\P9IM8^MCK1UX(88W&W*"TTGFK>.4&%A<E^B,TD4,"WC4UI0J[JS@MN
MUR7T.0:Q8R*ED9)ZZ9147&%VNCE))XVVSE1D19[[;LB@]?X.!Q%NZ8N=='#=
M336-;-=M2PZL\>#D,)3!^8@AG:=I_,9^1*/8AF)CVGJW&)RE+-XRCE\<Z'T<
MC65;K-B-I)3A@H@Q]Y!@3,@U<_<M@F!1!#,=(N]F/N^9\QV 0YKY9B BV[\'
MO&X25GS"1$M"X-(GVR:+>(#@8)RT*SB=I[KI)OAS4BP%Q\DHV%N]C9C0N"%M
MV!TE.02-_(M*M3*)-8!(BUP1[RTC.)%29VF8*1DC'<HX#Q,H.[E][0TQD&:;
MTO43E\^!BBT]T,;3HV6;"%1:$$#;U^)*(-0L6JNV14<N=#4+7BZZE_$?1<1F
MY3==V Z@J*.3#J).^?ZD7PV%Z:_<JZ$(:#C3>WA[-NAC;=TLXW:OVR&JBCIV
MGA/;?3MCCM#,+TH/3YIGC#8N68F2^(XM(_2S,S\1$3$S\1/4>'JCZC*J9S+\
M=?*C ^8JAX#$EQ5'W3#*2*PY=8"/N<E(L$8F2.-IF&P>K?W*P_N@IFE[7C8F
MJND&8UT1'"Q+IUM";.8BV^[HPXAFA5=R5#'A#9)=\2AI-^7<_E#9<T+,DV[0
MPV"KFH=+MQ ^JK,*S1DH$B*(\M>2G8(;QB!,"F8@6B(QRF!(!F1DY6[7]XZ>
MN6SALK65BM1@HF+4HRFEDP5')Q4X:1-384,2;*;#:7B$G*<T0<*98VZ0XRZD
MVOCUC:3AO%YT6AJAV>0JN0[J*E 21(H"F:IP6:S'/T42D&A4F!/R 5HX*/'R
M1-Q@VP725+803\?J6O7SPH3:!^5H"#SKN%QQX^ CPEA1 %Q4T/L!G-<%$Q$<
M9XV!U3V6SV0[63GLC@K&-T%JFP[&ULO0=0097/5/;+AJ*8=I(MNT;.UBU2&M
M;8I@$;(>ORP=IRYJ3K*F;B]5'K]M*;/.I:<@EQ"*TE]CL&3<;(K19&C9V=#X
M[)]T&P%J="&'YYL)V> 1$:8+LDR"+XPU8OBCDKZUPV=U<=>],RP+$1:6M)C7
M,*D"IRE%REC)5 ;MWB/) GXB*-HZS9GZ:.Y7;+L!3U%@%J#'7<7Y,+:M9&NW
M+5F9\VW,=>O5_"NM47D#LC%*0)D566*L75)*3GK@T<Y4]P%E>LZUJEMR=R92
M\B=RAS\4C,NM,*0L635&P%[HR>$E+)92!Z*19&I,LR.!!A^5ZZY8A"(I^Z9B
MBP]ECUW.K(RU3T^DI%1\539%/*HNT(D?)*Y9XH MB63)+QK9 <)*9DM_GT2Y
MY_;S5*\QWY!UVF)9!6(L9$0U!;P=AJJWAREH*OKFV% 2[::P*BU<JS9]0M<0
M"H"(-Y=1WCZV>*:ZXBZ1K.NKYN>U'<CLY6'7<\4M"$4]3*A1D$A<:7T!G$4I
M')W$SC$TD(1<-+=1<,T^AJV</U<HMF.3MOH)V4P+JVJ"\U9=DP&IR78(1D%F
M*):4-6,)+]+$KY[2Z!682&\>/K&^J7%Z0[NT=0=B@+%Y5^%K-=J!2+F'59L"
MZ]6LY-=%)4+C)R"2#'M"X-;S#CVMM5W#9B)]Z?Z:O?V:<03;C+FJM*^HJX::
M-16PW,#I1_M5\$N*EE7!P/)@ ],Z<W;Q^1,)R>B,ED*)V6;"YAOG9UN\;/-%
MF+KQW*T&_%X.O6TP7BJG9$2J02JYD(BTS1#!A2RAIE#YY\.1).#(I*-]CZ-/
MJCP^K.Z^5U%WS LCF%81Y)U"ZO<S2J]MCZ**^4.DV;]Y14ZJ6XP(JQ9\ 7TE
M60E2CA4O)MRO[A*[];5&U-3L]E'\-8.UI"9GD=AUJ!1=B1ZLR#?7$)A["RB$
M@&CWXJ.F-"+\\+"2M5'5L:$"F"A $"=))>^V5>MB:45]62#6PMLUX?!7%UA(
MXF$,E<-@S@>4K*(,%[R %&P3UH_6MG+?<'5S<QV&6ZCCF.I!E6XZ%Z?M9JPJ
MN8MRM9=F:3*J&-):[*S]-:MDJ+;TS+'1/?;NMZA[HJZH/5#WC:<V9=4VC"Z3
M&63,*U&LMQ 2Y7:H"01(28D.6K@$\-20NF'2=IM(X0C3]4MH[T>@LNQ[UCA/
M6N'P>KQJT=X:;S"JIRC) A;B00AAP<,!C08,JX\N/,(84;D,[='Z9NX_<KZ?
MWZGU "BQ=/%A8S-RGD:ZLJ]F ('97)4ZTI.K:K8]]5T7O(2O/->T5-+)%9Q.
M:I#/&O.+^C?64G-6THL**09@<@<)L(.[E)@JA'E"TM;'R!W,<Q#&$IT6%&9.
M(&).!;X<T'Z+A1S1HD,QO\O:DKV,ZRLVT*<K>$W^G2+0&5R!;A!C$A&ZEE,@
M;.9@,D4%RW+%IOLQG\;VM3J*C@7W] Z9LUL4S,7W4'F-P+*!"P51C M,$+UN
MN$6Z]+TM>PX$K-<J(5,(\R=<KK\'3IJQ:N7KUP@S9LT%G3MVZ530;-6K=/99
M=PX75VT21002TW5554VU333UVWWVQKKG./L1,S$1$S,S$1$1O,S/M$1$>\S,
M^T1'SUY,A 2,R$  9(S.8$1$8F2(BF8@1&(F9F9B(B)F9VZH?OI_$O:K[@VL
MKLF7QR.\WQZ5:[-',W/C(X"UH*GW*C@2#PL>=LTT7-JF=L+/QR2RCMF0L JN
MCC[8?MNE+XH9IW3!+0HSO,7[PI9,/UEJ(@CV")F8KA[04^TPD8GW+::*G?J=
MU.[X6\C;KU].5K42)7;"JZ(P.'*24CD\@B"RK_<UQ,F#,@V8^U<S%@OV_ N9
M^O.)I_&8U>5%$+.JS3%L52@SM. *OWAR),7?YQ%6"2)[ZZZDMB2YH&/')[:(
MKR!4 X5UWRP2QJEZ99>QF60PZML:]B?369FN[C ,F.#)^SVA;8 R+Y@(.(^9
MZL!W=KZ:U=HK(5J^;P;,GBX_%L5 92A+#?4 _-57$/W*;=0G(6N/M)\H*8F5
MCM&+\.1V#_"%2TTY$EQ3ZTJI)=>9UQHZ6^9R_JN4E,[&1K?7;.RJND+FS_?=
M513?&J3":A![5/5N.SC7H:YQG@MJR:AV7;B%/VCVBPL?M*?RCRJB/YR493.Y
M=+'TZ:O_ !#"W=(VV[VL(17,=!EN3,7:;,N6,3,S,4KIS,S[0*[J%C'%?LW/
MV:XSGU\]C8QC.<_Q?;(S^W^+$?=9SG^C&,9SG_%C'BU@/XZQ?]-1_EQU+?<O
M_<_UC_>_DO\ 1SZ2#^%_V^,&[#U^'\TLIG;X_P#B#V+CX?U?)_M\;>X$?IL9
M/_LK4?X#1_X]0E],4_[!U?'[+>&G_"G(1_\ 3J#-2YQC\1J5SG_*ZNK']>8]
M/,8_VYQYUK/]8P_\VU/\XGI'Q/\ OBF_WVYK_1[_ %V[\31;\D(W3SKSX@[<
M)14!6KRW7(Y)3;1J3DTTE4AA0YV\2^.$UW 09!R"(U3?&=FB<A*ZI[8P\5QG
M4T#56-6]=F(EAOBK!;>XK4L'%$?L@R<,E$?,@._Q'7;^I?+V69G3NGQ,HJHQ
MIY<E1.PMLW;5BDHSCX(DKHL%4S[A%ANWL<]6D.3>;X+R;S_6M&0$2Q'#X='!
MJ!U^T;II.I3,5F;?:52\POIKJH]+2$QJX>KK*YVP@ALV'--4!S%FU0C[)7G9
M*Z^XXB(FL*0B9]EJB9\:AC\A -AB(^9W*=RF9FT&D].4=*:?QN#H*!:Z=98O
M,!B"M7" 9M7'%$1)NL.@C(B_5'BL8%8  QJ]L7-D(Z2X8OH=)Q#%Q):QKR7V
M]6Y]5!+\SCDNKZ/OI-IJ.>[:Y4:MI*/%NHN93^.4' TJKNII]PV:+M]_3E]M
M#+TR610M[U5GA$_:Q3SA?W1^<K(H8/YP0QM.TS$K?=;3=+4FA\\NRD#LXS'V
M\OC7R,>6M<Q]=EF/$<^X#96HZSH^"4TMXY"$BIG\,G<4A/U3TO1Y5XX= *UE
ML#GD3274W5U'8LMC*ATD'M?GSG[9CA[ QQ31HGG5') L4=ZZ87=.=U&37U4
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M#(CJ&1[,&S'&,IIY'+S-(5+Q3=)+&/HHL&+=1KKC&K=/7Y<>/'XUHMT^9N.
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5.CPZ.CPZ.CPZ.CPZ.CPZ.CPZ.O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g553370g53b65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g553370g53b65.jpg
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M 0$! 0$! 0$! ?_  !$( $\!4P,!$0 "$0$#$0'_Q  >   " P # 0$!
M        " <)"@4&"P0# O_$ $40  $$ @$# P," @<$!0T   4" P0& 0<(
M  D1$A,4"A4A%C$7(B0Y05%A<8$C)3*Q&!HF0G<S-%AS>)&2F+*TM[C7_\0
M'0$  @(# 0$!              <%!@0("0," ?_$ %T1  (" 0,# @0" P<*
M$ P'  $" P0%!A$2  <3%"$((C%!%5$C,F$6,T)28G&T%R0U-C=R='6!E!@T
M5%569821DZ&QLK;!TM0E)T-$<X*%EK7$T]5VE:*EL\/%_]H # ,!  (1 Q$
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M7L):PY$-)DA9,1HTAM'ZCFLN)G#(K5<&/C)1@K9'DQQQT4:03C)BPS36#(#
MU<JW&-4Y'9P2F_R ^S$NP8*J6@JZI755ZW8R6.?2+XR&*ABTK$9*'**\1FL3
M6/" T+()@!ZB12'B45XFB>:9F.L#JS='1T='1T='1T=1/O;<E/X]Z<V5NV^R
M?C5+6-0,VTOA"T-R9R1D5;D,./\ <SA#A4Z0S$"B&,_F24GQ(Z?*G<8ZR:=6
M6[:@J0C>2Q*D2_D.1]V;^2B[NQ^RJ3U%9W,4]/X?)9N^W"IC*<UN;8@,XB0E
M(8]_8RSR<(85_A2R(H]SU$W"7EO2N;O'2E<@:4.<KS-C<*BK'3Y)-HP0I5L
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M)6TZVI2'8%)-CY3>6"*?5?-#8SSVY<G*N\50&* D>S69%^9A]CXHC[C[-*C
M[KUK9\1>K_P_"T](U)>-O-LMS(A&V:/%59=X8FVV(%V[&""#L8Z4\;@K)[K9
MV#;[PNXN:DV3N3=W(S2E%W-MPXFM#JU:;P"&V.K:SI[Z\,-RX4J2W,&2+A:'
M9Y.9$>1A,L0!J1%O.4/)ZS]90Y7(68*M2C;FJ5D\C21PNT<EB4>Y! V811\5
M!'T9Y5^W5;["W]&:7Q.2S.;U'A:.9R\_IHZUJ]!%9JXVFQXAT9@\;7+1DE=6
M&SPP5)![-TUO>+W;P$YE<-K8#IO*G0AO<.J9K>T-51(5]!NE#!,/'>C66G0?
M0_AZ2Y;*M()11XYM>&YUGAUE;F%9BM93&Z8J9G%Y2-Y<==2K8'I[),#A55B#
M'*WML!%(%+-]1&9/L3U:^\&;T%K+1UN"GJG SYC%N,IBD2_ 99I859;--/FW
M8VZK2I'&#L]I:Q._ =(O].!S#_1VSKYPUMY3VP&U6Y>QM4HE/8PU%V)7!2$W
M #$2I7_E+73!K!A"?*6FG:,ZAM.9)7/KF-=8ORUX<I$OSU]H+.P]S [?HG/[
M(Y6*G[[3#[+U1OARUAZ/)W]'7)=H,J'R.*#M[+D:\0%RN@)^MJG&LP^@!HL!
MNTOOLGZ5W6XO7GC=\S&$]TSE%C&/&/.E,_ZJX[ZD5G/^N<YS_KT[-(_VO8__
M '7_ $ZSUSW[X_W4=4?^Q?\ H[B>MN')G&'.WQR!QY_E7PVVMCSC^Y6DCWYQ
MG\X_;/XZ4]'VS=,_EE*_]+3K=?4GOH#/_MT=E?\ CPL_6/SZ=W^L2A_^">S_
M /ZZYTS=;_V$/^%U_P#DDZU#^'G^Z&O^),G_ ,ZMTV7U.E[,R]P\8-9*?>17
MP.M;A>VXR5*2P^9MMH9K[[[R,9PAYZ)"I4=N,I>%*C(FR\-91B6]ZXW0$*"K
MD+&PYO/%#O\ <)'&7V'Y F4[_GL-_H.K7\35Z9\OIC&<F%>#&W+P4'96FMVE
MKLQ'T9D2DH4G?B';;;FV]YG9<U;7-7=N'CLD%$C-3M@@RVT+6090A+YFQ7$Y
M/D)E3EHQC#L@: C JVRI7\Z( .&RORMM2LU'55B2QG+W,GC ZUXU^RI$@&P_
M(,Y=S_*<]/'LSBZV+[<Z=$"*),A!+D[4@ #36+D\C<G( W:.!8*ZD^XCA0>^
MVYM.ZKW31ZR8_4[:MKC3?%C=,2'&C6R:[L#61V:AM.)1<! ;"6BLL2%XQZE-
M )\VU*CXSG/C-A?QG\81X9&@+$F^1J$DQ@0V$'OLKDM'(1]MW41[_P!X.M4/
MB:Q=8+I;-*BK;=LAC)W '*:N@AM5E8_4B"1[17_"&_9T_'9CW#8\=HR/993C
MDXCI.)OD6 <D^7UO0:J^9NP6*K*\*]QB#]Y0)BM9\H:A0H\5.,-M)3B&U353
M]TIC  6V:;.!_&D"1.?V%BI8_M)/WZOG9K,6?ZDB67)DDPJ9Z* M\Q,=5IKL
M*>_ZRQ^81(/H$14'LHZS2=E'7H?<O<PTD[>DI/-5J3>=KOM%,_*<*VJJ5@P:
MKI!];V5J>F#K<X*LN'5>M:Y(O"EYSY4K%\U7.U3 VQ#\AD$-8%?;C')(J.HV
M^@:(-'_,W6MG97'PYGN5A6O?IQ6:]EB)3R,MJK6FFKR,6W+/';,5G<^Y:+<G
MZ]>ACTE.N@W7"6:MA+E6[!4+,.C&*W:@A6N6 1,1AV(4"'($@85'2F\_AR--
M@2GXSZ,_A33JDY_?K[C=XG22-BKQNKHP]BKH0RL#]B" 1^T=>%FM!<K6*EF-
M9JUJ"6M8B<;I+!/&T4L;#[J\;,K#[@GKSS.UI7FZEW8./=5:D9EM5G=%UKS<
MI7I]4EL+7;L-1(SZ,81Y>3&PYGTXPGRK^7&,>,=.O4+F73EV0C8R587(_(O)
M"VW^3?;KGQVOKBIW6T_4#<Q5S5RN'_C"&"[&&]O;Y@N_M^?5X7U/-V,#]3\4
M==1WWD K9L'9=Q*,)4K#+Y.@UVKA@JW<8SZ5*9C;%-^UA7GQ[BU8_.//52T!
M"K6<C.0.<4$$2G[A9GD9]OYS F_O]NG?\3=V:/$Z5QZLP@MY#)7)5!/%I:%>
MM#"6^Q*KD)]M_P R>JI>V_WB1/;OTM8M5A^+4'9ARVWLA=['?GMN*ILTE[HL
M4'#A<BD:PM*VX *&,=7$QDPXVJ64)RD1XZYCV%V/.Z8;-VTLMD372*%88X15
M\H79F=GY>HCW9RWO\@]E4;G8=*KMSW@A[>X6QBH=+)DY[=Z2[9OG+FF\N\44
M,,)B&,M$1P)&2GZ8CG+*X52YWL%5]406SG^7A..QC^S"N0TE6?\ '\XTHG&?
M_AQ_KU"_U/E_UV;_ #(?][Z8'^B?E_V%1_\ O"W_ -DZJ^[F?=3%=QZK:P%D
M.-@_4MJU?8#9 7<XVSEW>5,K]C',QC58=@.:]J2F6)1(:!*M3,DI"8S@MUE$
M%69[C[-@P&G6P4EAEOM9CL(BM$:_B =&)23?S2;D*SKMQ&X;??VV*Q[E]TXN
MXU7%Q2:;CQ-K%V)Y(KBY,WF>O9C59JIC..J%5:2*"4/Y&"F(J$/,LNB7Z<&Z
MF+-P(M%=)O//0]=\AK[6:[A:E*:BA2M4U_=WH;'J_"/%AM9^:XVCPG"YWN9Q
MZG59S2-<Q+'F8W4;&>E#(_[762:$$_\ J1(/\G6PWPYW9K.@K->4DICM0WZM
M???989:M"\4'Y?UQ;L.0/X^_U/67WE)3Q.P^[-NJ@'O?^QWGG=:*>9^*[EF5
M]ILV[7@I'XSV/.6G_AS7O9=QCRVYZ5X_;I@8Z5H--U9TVYPX=)4W]QRCJ\UW
M'W&X&_6L6J:<60[L9K'S\O!>UU9IS<3Q;Q6<T89.+?9N#ML?L=CUZ-0($&JX
M,-6JZ,A!:_7A0\&"##8[<0<)#B8C, 8,@164I:C0H$*.Q%BQVDI;98:;;0G"
M4XQTCG=Y'>21B[NS.[L269V)9F8GW)8DDD^Y)WZZ*000U8(:U>)(*]>*.""&
M)0D<4,2"...-!L%1$5550-@H '7V38<4C#ECYT=J7"G1GX<R*^C#C$F+*:6Q
M(CO-J\I6T\RM;;B,X\*0K*<_C/7X"0002""""/J"/<$?M!Z^W19$>-U#HZLC
MJPW5E8%64C[@@D$?<'KSN>SBXX%[I?&1J$\XSAFZ;#%)7C.?6N)*U?L(6^TO
M./WP_%><9<_'C.'%>?QT[M3_ #:>R&_OO#"W^46(6'^\0#UST[/$P=T=-*A(
M"W<C"#]RC8S(1$'^^5B#_/U=C]3_ '(O!U]Q!UZP\ZD#:+CM^Y$XZ5*PPZ7H
M@6A! CSB<?RY=8A[%L"&<YQY2F0_A/X4KJI]OXE,^3G('..*M$I^_&9YG<#]
MA,";_P PZ=/Q.7)DQ^D<>K'P6KF7N2+[\3-1@H00,?MNJ9&P!]]F;;[]58=N
M_O'O=OC21;4-9XSUW8,^Q7DM>;'=Y^QYM:(EI<X>*$CX#@^/2C7M0@PT0PS$
M;^XN-Y?D3I:&6'9K^%V'-Z7&:MK:DR$D*I"L,<(@$BH%+,Q!,R>[LQ)^4'8
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M1#&2\D$+.K20Q%:<M'\@NWOWM]EV6I7_ (UV>5:M!C\V6F&;F5(!))ZB3CK
MY[,@CKRS#)#;."KP^1,I-BDEA;?W)4H=(ENY+>S*:KT!5CBHV<O#6NGD8T,;
MSQ/"_'R&)F1HFEB.S$;DIR!W0<@6JG8OXJ=21VM2XCM[E<SIE9(H[5N&U5Q5
MZM>KJYJI=BBMP7XJ%]/(B,\(CL&-HP+$BQ<8TR[FXSNP5KG13*[Q%&[]"Z)!
M M9AN/(;1D0_#T^-BC:\&@G!NPX5?0B@QL0+2R;BRXNR6T"8E%:$H4ANO)SU
M=]-1Z6CP1CN)CTFC$B6$G$:S)&C%8%J*=I%181&$%8 ^0$#Y@.M;>[MOO-=[
MD>LPD^I[52W)5M8^SCWN2T[-RPJ2Y*?.3(35EL39%[4EJ3+,5:JR,Y,)8GB.
M]-R\YU:7Y)T&EU78MZT]0(NN*B?KDK6<\I705\M\A#F;O-EEXN&W[$@4=3@*
MBKE)4J$/%1QDU\0VZ><E3]9-=9?,TLO'!3LVJ=$1))5,+-'ZABS>1I73VD=#
MQ1HB610%;A^DY-VP^$_MOVRU1VYN934.$P6I=429&U3SD>3ABNG$0I%%Z.*C
M7L;FE#8B,EJ+(11QV)I'FB%D^C$</X<U>V59>5>C-.<\]D[AU5QIW[=M4Z^8
MY"#]^3'M=T.UV:$$C!JW:5%8 R=+J%]-U@<'CE:8W69$67+;CQH48%,@3F2#
MUT=KS\&T[1_=*OA3PI(TQ:*!XI)B7*/',T*;RL3+XPR/&[N@0@ +R[^('X8Q
MW [Q:JK]E#)EI1E;=2KC8(;V4@NTZ'&$6*US'P7[)BH1J*)N213U[5:M7M/9
M1FDEG_OC3VY[KP;XC[[YU:=VYKWD5R/:U;.#Z8):*=5>]>T($7L843LZ[5\Q
M/'L2+?=P%+S8WHS$BNCX(# PK!FC33\Y2(.+KS7,N8TW;?3:\XE19DG4Q3R2
M\)55V58FEC KQF68KRD;R1J& "%6F_A>^&JAH;O5IW']YR:5F:[)C[N+M17<
M5!2\U*>Q3KV)KT5*X3FKD=''><1546G=F,$KF>.>/F.S)RMY\[ON'(VHSK[<
M=O@(6C[A8ZO8MID9MD%T_=V7H,;6PYNSFE2'(8^P/RBGS:I\O$!T<,>*1HD5
ML5)R^GNWF6RE[*2PY*Q:N8Q426Q+*S2M"WGB'&.5MV5I(C-QA!V/#DJC@=^A
MOQC]O>W^E-#8S):.P^"TWK66[+1Q-'&0UZ,63J#&WI'FNT( D4L=.]'C^>1>
M+FIL>GFDD]0@3E>TU6NYI?.2VYJ7S7"[]LW'6U4"[@-QU_DM$M,RCESQ5QB"
M+&4*)<$Y$NO3,/36)+%"QBLJJ2W<R,88365)V-U=#IB;#QPTTQ\DLQ6-8ZHB
M9GK,C+,MH)\Q0J=CY_TGDVV]^?7'CL9D>\>*U[-D\Q:U31@Q_.ZUS+/<B%7,
M5IXI<?/AI+&T<=B.9>8..VK>F!Y KZ?IN]D\H^WSV8MV5GCWKSCO;0A3=HZN
M7C8ULJA E8W 56(6(_6:V\^0O5B,6.P-#9HVQ2D50-*A0!T3+DJ)\HL2=BKI
M^E] P"C=MXB*M33R,C+(\TDMB2*,2<#+*TACC02@("W ,S'B/F8OWO;\4^=O
MZBTYANXF2R^HYHJBS5WKU,92HXJI>LM5>RM.C!2AM6YY*9:RZPFPT,,2^9]H
MX5N:":;TC1=AV3;%?UQKJJ;/V*IL79[Z-K@(1;K<XXI$OX! XS&8(DWIKL!F
M9*8R^XZ1?'QY<M,AV$RXU#Q4*D5B:W#4@2U,OZ>Q'"BS2*""?)(J\B"0I8D^
MY"EMR!M=K^K=1W\-C=.9+466MX'&2[XK#W,E9EQU.8I(J>DIRRF&-TC>5(0B
M;Q1R2I$$1Y 9:ZR>H+KA["?"U, <M-D)1 U=K0<F?/&)[N&((H*&A/D2A*:\
MK\,Q(,&,_*D.Y_#;+2UY_&.OI$>1TCC4N\C*B(HW9G<A54#[EB0 /S/7C8L0
MU8)[5F1(:]:&6Q/-(>*10PHTDLCM]DC169C]@">O.KV,?V+W;^Y2ZU7G9<![
M>VSH]5I6)D9R<C7NGJVTXQ"(RQK<AE"TU+7H>9;+'%BOQ4$S+9E]I;4DCE>7
M? D&FL""X!]'7,DNQ \]J38LH;8_ODS"-"0>*<0=PO7/#(V,CW:[D%:[/&<Y
MDUJ4N:F08_#UP0DCQ!@"*E")[=A$91),)F!#2;]77?\ 5=P__IKDO_E[B_\
M]IZJG]4%_P#6I?\ /3_W7IT_Z&&+_9K)_P"[R_\ WKK^T_2\!/'\W-4KG/\
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M^\;9'TQ2K=,*2)9 RQ/@9C.1_;4BM,ZGS][43T[D*>!#.TT'IPGX>80S1AG
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MJ[.& <,</O%\*NI\1W4O_NEO?@DD\E"]DJ+*+=AH?!%&DV(O5IFJV*UN.O\
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M2WENO+;BPHS+"%.N..J2WC+BUKSE69:.-(HXXHU"QQ(L<:C<A410JJ"23L%
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&='1T=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g553370g79m67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g553370g79m67.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MJF23;7EH,1+LAE&3(&0%Y*%>"B)E4;.PG^&9Y'QC^]O?HW.??^:9FLTX]O\
M=G7ROW_G^_O_ )?[57Z>Y+_P='_58_\ []77_HTZ2^N=U'_Y\9'_ .?/2H<=
M#)GB \MYKD,_8S!+G_IX%4P])M%E7%8>)S3&92]560E]DQ!'K+#[RFVZGGNQ
MHL2*X\:?*YCL1VXZ&V.4*-3:;#)@L1NX\V$U:XF=A';U"QF9DN$I\=D=YF8X
M<=YG>>JIH]1]HN[3M(OLN9I_4R*B:5JS(#+6.Y3BK+> @N7+O>KQ1R @,R\F
M\1&!B)(\GG_;O>-G_P IYL__ $EM+U'P'ZGY[^G=_L-;IEW._NZ]MOV.F_\
MF3*]>^2/.<>?3QV>V?;_ *,<[8_RSOO<6,X_SQ^V?\/6<%^IN;_:7?['5Z.X
M_P#=[[>?U73W_'<QU^GY8JCLOB7R*<^>4^G4XE==7Q&P-6VPT+0K+H4G%"F-
M>&(!"5\5,"&+OK(\D54RTU*A[-J%28Q!Q"I(N--\Z<8C+8.[IYK158F396DO
MD8R8."1CYE*K <F"/Q>,HF(G8IC9W7J9+17<33_=*G39=Q80BIE85$[I:*7X
M]RV%^5,7<98\51IQXXM*(63$DH66,'_.AXXA.IW=FCMS3+"54)5+'ZJ'TZU,
M;*F&?M\N)K;XV<)CA1DQ,C&8KQB>=:JZ5(4_&.2XZH[CZ,-(YT[,5RJ0L>6Q
M6":N40._\)!"4D4;>\ (2SZ2$3OMT6QWQ[<IQ4Y->9.PWQ2:\4NG:')&[CO%
M8E,4*5'R^ G,?%7>)(7F,C)(QX-=/;8VUOSJCR:[9K,BH1.A)=J!:T%R6GT-
M%QMQO4&[6TD%Q+:8D2*O7'*Y5ZE7C66E-F5QSC:'/F-?R\WU=:K5J>.P%9D-
MFE"S>43'PDI))6)[3,0P^;&L#VX;A[?%&U'['X?*Y;/:I[F9:L50=0':1C%%
M!1#57+P7;3$\Q$BJUYKU:E9VVSN+X_P<S*E\C;JC^$;NWH[G?I@+80G/6ZBD
M S1=EP Q Q$B 01>PO:\NL>$/8D3# *77K(1KUYC5]@J8!V<7'AI@RL#9>%,
MLG4G5F'HWJ!+*[5$@=7(X"9,Q"'IY%,")P:Q-,GQ$UE,\HY1U4])9H>RFNM1
MZ>U*FPG3^::#Z.26AC0!"'6)Q]T06)&Y!5[+*]X40UJ+*A" /QGN\ODL\P'-
M-WY>VQHGD^WRM];6W%K:Z5PABG5NS(!4/6K]9)3-FVVQE# <4TK([7\6R*:@
M#,S)8YS"BAI(Z!"SF2IP.F+Z<A6MY)44ZU5ZC'RL7S=8A@Q74L0,OS.E?Q%M
M!?E'D4^UX[D]W=-7M+Y;!Z4MEGLKF,;=KLBG6M>"AC9K-/)W++6I5'X6/"S,
M J3-<_BNA:PGE%?C!YXD=6^#C>.@!\J-"-;#O.U8]8DS5Y;@-W&OR*1;*9^1
M>PE:F!R[4!#MD)"$..1X2WWFVG5H2VK?J"[&.U;4NS$R"%5I9$?FE1PU;>,?
M4O&9<8^L[1O'SZ5=L=/%JKLAF\ LA!V0O94:IG.P1<05*U3\D[3(KFTA,,*(
MF1"2F(F8VZ4#QQ;?\<6G*M8>5/)=S+JW7&_-46RQC<;"VII2/9)5E@3B<@LD
M%<"T&O&C$"P5]^9*AB21)C-<*U% #\:94IIIJ2TSM;.VF!D<#?L/I65++P5[
M4K@)@8'FH2,1(#B(DA&8,6<^0?6*AVZR_;K#5;&E>Y6F<7C<_B;5E?WAE<*-
MDK*V-)T(MN"N]P6*\F0)8P?3.IQ7\3IF(@K']5[N\'N\^FZSS%ICD+6>SC%H
M@R'(.PZKRN'D:_BE(GS<D#B2YM>A6V' B16U2)]O=JWZ,'MJ;=FGV8F7I;**
MS4U;4H,R%K)V*XK*(E#,B4.D9_OAV9*IF9]A5#/*7]Z$SM$]&Q6:[(YS4U;3
M.&TCC<FZT!2&1JZ746/%H[R2V2=<+0+$8Y'<FKZ)<3$F\0W.('_B80PFN:1X
MXKP ;"# @-POH8*'&QFH8X4)%U&J01PT?#82AB+"@PV&8L6,RA#3##3;3:4H
M1C&)F@B([F4,RDC-22,BF9(B)K)(BF?>9F9F9F?>9G?I%]I5*JV#T?7KK!*$
M7;R4I4, M2E4ZH+6L!B! %@(B C$0(Q$1$1'74B*_P!5C?\ P$/_ -NWZYZ7
MSG^>?_GKZA7_  :_Z _[,=<N4S^[_$^BO?\ [REN>WM_3VXO(Y_?_)O/\O?^
M>/\ 'VZ"/Z@'^VC_ (H/7R^<[?:;5_E49B/_ $:R?_KU!W?VHZWP?Y25]>[V
MY\"=!\9]%R77;3"/TH%>!M;LYT+!AVN*S$LL9\)"O@FPB,7NL-S\CDV2M$2M
M>%E&WV#LP;,PUEF8T]]V4[ITLI1C\.0<:B8L"DES,A,'*2 _"S;EXV"+"':0
MB4FOL16T)W0G5^<T^C4&C=1%,VPL4D7EUK3TK"T(A9 D+O*L)]=5AGCBS68Z
MNIL$+S4U^R.V?X>^E:]7<JQH7GK:=@?B-O"M;U#DT2.M<R4[A.,Q9\JX:^K=
M;!HB+5_IKY(VA66D.."V"J\--.K48K6K7^)ER[7")F">W(E*XB)^<0MQL/?Z
M0(?SR/5JR6M?L_4L?-RK@=/92P01*L;3TFE=LSG^\85S'UJZ("?SDQT>T3*A
M;.T3:5HKEKQX;YU'1-PU#AG1E<K>P@,:Q!P]^YAU[4K9$A2E+0S^5"3JRXMK
MZZ&L2(4V+(FBRP]V*5$$" R;$F/UZYD<W4LNK-RULV(.5D2;[F+F8^?$Q9M.
MTSM,3$$)1(E$%$Q'4,'I;M[GL30S%30V#K5L@@;"4W],8^I; "F8'S(.M,CR
MB.0&!,4U<@U+&*,#)EMP4/=]NN^C#6JMSQM8T^DWQTYN.IOTX99'-L4U45AM
MNJQRD[/UZXXE;4QC[R%\'$Y*I*)<S*"0HTFJ7*]YSZ)U+L54HL2RXF4BWU:=
MHCQ09>ZI]BCD/O\ '![[K&)[KIK+Z4QN*U95U#I=F>R>5Q U-,Y$,G8HCIW)
MPPR+('73\%Z)@E'XF[C/IYKR/CMM-=1VT]:Z&=#^5>IV?QM;3K](C0JS?[-L
M*N'[1"=ZI.P"4B]1R&N);XY^#3FJW:T?J<CBB.6<.W&<G3K<!CDL9K<YA-:E
MHNJ6J<+*'Y.R%BW<IUA(GP8042#1,VB(MAK"9 )5 [DP 9,<ND"<YJO[2&<Q
MO8WN-9R&,T9A+&)T_IS/YLTU\6%:S->1LU6UZ]!ENQ4FA454*SD+S&<4T[%F
MF+25,7,1MMGM$<4WZM M?<Z^*.MZG^WZDT'T&Q!N):.%#;%/P2T@Q(/T^5;K
MHY=XS%<+:C+5IH.67;",*PN#(*B ]CUL3GM/YO2V4R^J*1KMY 2?QLC,I4,'
M"U1(C #(^4(8N93S8LD>(?),1U&R7:ONOVT[[Z0[>]D-2ULEC-*6D8U-K .6
MF_?>RJ5VX0/8=AJGQ0M'4NB.2FM2N(R<7WE3%A%\2<7;X#GCMF\7NOT+I#Q9
M6C7H]GE'0_/3<"FD_P!+&-EA6:W,$2Z[3H]II7Z$'NS2NU2-FBG"F+@*FGL"
MYB(95+F;.?P&"TQBLOI:DQMO'K!TC6&12T3+QLV&88,!+&$9R*>2E"WR#Y-^
ML87M1W3[H=\M9]N^^&IJV-QNJK]NBRWGG [(475TE>J<W+;5:ZQ-.JBI4 \E
MZ>[<90]"[T9!,S+JW6NB8R_%74JQXW=HFJ4BL']A5'9]C.6>4KE8[.F?VB.K
MV,\U :'6V0<N4A=F@+O;]<'H>DPR5+!2"JUUZ#K])1UA6'5>8E"<K7&M:J4[
M(DNQ),A>P+$&+$Q3"PE<&EL?##"%13RF2S4&J_L\9G)]B>WEC(9'0^9?F<#J
M'/85BK.(;7J':@WV'6:UYM5V0]797;FMD*1R+64TNO+6*AMCTU0]X4^V[P*[
M9W/%VE6+KL:38=/5MBG#*RYJFB.,N)CTV01@9^M8W(^%Q8V9\W"G75#5E%N_
M=&9D:*NIHO)=>.W=BTI]B64U0D%341M.R9(?=NV\1R+WGCSF=SF(?ZGR^E,E
MCM*5].Z79@+^+PBZ6IKQY-]\=0Y<2&3R8(='"B)[,9X5;",/BO ^.JMC)UF1
M&)\25!DX<5&FQGXDA+3[\9W+$EI3+N&Y,9QF3'<RVM6$/QWFGVE>SC3B'$I5
MAC$R,Q,?.)B8WB)C>)WC>)WB?YIB8GZ]4TP%@&LMY$Q("V(AGB43$[$,P0SM
M,[$,P43[Q,3[]+WS]R-S=RNW:6N?-1U?5V+LX)=M;E?P1=D'% DD$ATS912>
M0DJ:'?EB:HS#;K;*%SI+GT\N.J5F;=R5_(^/UMEECQ04+@^,0'/;EM B,;EQ
M'>=M_:(^G5?P&DM.:6BU&G\15Q?K95-N:\,DGRCR0GF3#84POS-XQ$Q$293M
MO._3&^H/5BZ6_=_(7-72!VHVC=^H:ML*R4-M]JGGBV"48N ;DS(I!Q, @)GC
MI2,(GPH\R-]1US[.2E;\3Z#C[ZG)U3)WZ -74LL0#MO* \9$]HD8Y"0E'R*8
MGV]X]IWB(ZKF;TCIO4;Z=K-XBKD+-#E%-[?(+J\$8,F%L2Q9QLP!,=YG@420
M<9(IG,OO*7.VS]NT;?-_U16;3N#6C0)BB7TFF>HW66JR<(64"@<IF:S$Q^,.
ME2)./EZ,\K[B6[]3*T?%"<)R-VO6=3398NJ^3ER1VX,E@"L^6\3,\@$1GW^4
M>VT]>[^E=/9/+T<]?Q5:UE\9"!H7VPR7UHK/991"Y@X'\)[6-'D)?$<[[QM$
M>WCE/G?9.X*5OZ]:GK%FW)KJ.%BTC8!%$Y1VN1ZX8)GPC0]3,UJ*E(TR9*$(
M_P!6,[G#\U[*\K3E*4B<C=16;3398NJ^3EJ!F.#),1 Y*)B9^(1$9VF/:(Z+
MVE=/9+,4L_>Q56SF<<*0I9!D,\]8:[FO1"]C@-EN<U@[C/Q'.^\;1$WFP@6R
MB"5?L8@6? F8<@<7"&X$0J(*CY;:FI4 D-G-/PYT.2TI34B+*9=8>;4I#B%)
MSG'J(!FLA,"(#&8(3 I$A*/E(E$Q,3'TF)B8Z=N0FREE>PE5A#@);D.6#4M6
M<;$MBV00&!1,P0D,B43M,3'2(C_%5X[!EP3>8?(NG\'42_O41Y 67.J[<C#G
MU$Y:HLZ?(H[32%^V6X[==3';]L8;:2E.,8<%J+.$KPSD[7#;;>#@6;?+W<,0
MZ?Y^>_5%7VL[>*N>N#2.'A\%S@201U8+?>-J)L*E$1/R&*\#'TCI^HD2) BQ
MH,"-'A084=F)#AQ&6XT6)%CMI9CQHT=E*&6([#2$-,LM(0VTVE*$)2E.,833
M,E,D4S)3,S,S,S,S,[S,S/O,S/O,S[S/5]  6(@ B  (@  ,"( ,1 B(Q$0(
MC$1 C$1$1$1$;=5;^4+H7B[2-;U" [@T>O;NL-GG;6*%F$4L+<OT > CPTO!
M#+4Z8--B,EH1&0S@G4IWYQ"8#C*8,N,Z^N+8=/T<K;.T>)M^FL5P41#Y35Y@
M,CCCN,$!<9&/A;'">7YHG:)Y?W/U!HS"5L17UOA)RV+R=BTI3HIIN>@L(6D_
M)L9K>KR@PH\M0_/$+D868R4C2+T'W?XJM:<V;?TIXX]%),;HZ3I!G3BRP35]
MH%$QH.^L9!FXLZS7EIR\&'W($Q]%?JM;22'S3^8#TG,9$=*W+92P^HGWZUO.
MW.-6@X;7$["R$C3/,)%:9A(1RB.;#XS <HC??KB>H-=]K,;IO,83MS@X=FM2
M4G8>6HQ=I35HOCX'"=F\,W7%(&45ZE:&+.Q*R+C [S:KX[M>[A\>GCYTA6KG
MJM^R7[8VSX<ZVU!^V#JK/H9S=]ZKE,H 8CF>.()>E(;)5S-KC8PR_79JRL9;
M<MR'\5T/6V;%N4*U31ZM$MJT .&BJ",V+0#(Y"7)9O;,04?X,8/WWVZ^G/LY
M=MI5I$,+J#+3I_(KQ^=U582>.=D)!%*C;RUNJP4O22;2<7CQ+QE!<K;"K3(<
M).91Z"(<*=&[ 3KWH+G2F[+V?7[_ ''6CBBPB)FV"(5'T79=[3BD6[CVA9?-
M9E1:\_7(8E@VA2C,Z.0>@-Q$O.(1U-7V,<\ZM2S90WU3D,0L]P@D4672=('$
MJ*)%<J&=N<D43.P[[=-S'V>J6K,2G4.:Q6&R6-+!8O+U,I:JR%D@RNKZ.DD8
MT7*.+RV+=?'(-'EZ:$*-8R3I")U+2.Y>5^7M(4_96G.;-*:* ;7N\:D8G(V%
M3J-&<PWJNQ[:P_L/:-L BW?KQ1M>4(&B29 LR\:)1&84]M*W%8A7-8V;M6M>
MOME@O?"5>JR"UH5O49;DC-@ E,R"^$"(_&9#$%U9,%]G+%:?U!G-+:91*+&)
MQ'WI?^Y-(6[V3OP.HJ6G%*K4\?9MY#(*BS=]5+VM'P5DM.41,QO,FW[CR%T]
M<.8=4=!Z,'W>7M*DCMEU@3M,8(1.U*4V+69YBGUVU@9)'! ?8KO%I-W X4/1
M-AP+!34!)\A$H\"^\ETM4,I6J2*CK--V3JJ<6Q"HT^4#;619"2Y0;?%8 >,%
M M5XRGDQ>]=U!V-5J#!:JRN9J8;4%#0N=OXQ,PE]ZME)QUNK0SF3PUH50@ZM
M",AA;+)<2F6*&1BTD"73M^/P9Y(:9/JMJ.#=?*E8JYG7P*.R,O\ 63(J,Y?M
MA&=<C1MS* V2<F@6D5*!O&B52+B))/\ !2H4N"J9\I28B:-2I-36C7DI6RN&
MPV%&,39LG6 7DOE-=HD$L-1A)0N1*)GWVZ,WL;DJ][&46YB$C=IYBU,OPU^K
M8)>%PE7--=BZ]LD!F,?85:"I7R-:R"/5K:IL*V7+,W\ES8WMTCTR6YWJR.@Z
M_5N;BDC9XW(XI9E#^E;,?T37H@RS/1!LJ0R" BGF23C\"'F4$F)'QF4O(<].
MHU):BF=$C?%4 QCBK V#1/WG=-2N/L/+QM7YBF1'?>-HWWZYI/9C$LU!6U A
M>-+,V+>NL>G,6*!HR0?H+IJKD+WF@6/\?K*5N<>@ <V%\")A2LHZD8YO"#=H
MNVJ%N+0 DA1ZSNG4_.]B%GCM8OH&V']P3=0/AGI=:(!$0G@ \!N6I'2.""'W
M,RXQ(4Q&6_%:ENQDYAZ'//P-K%4OU*(N39CG+K94_&82$ 0"*[JC*=X+>#"(
MWB)EQD.V^*R&.Q"@S-/,JU%I#4>K3Q]["M77#&:;7J2+=:Q#VV%/>^[I;(U4
MAXY7Q*O9,Q$Y 5 H>@>+*4!LW3FO_&[2,5T1'?LFM;4/#5:UES^8=PC5F.=B
MZ_4D_.UY$^#SMXAD@H4J1#4D62)$AX2QQ8U8E,FZQSEFBYYGD6TH"93(6!D[
M(0V$[M6G\85E$^;<O-,($R8 LB%%5*OV>.W&*U1C<,HM(4M3':6K)JLXERZF
M&LECSR,+I7K_ !QEFVI@!C!%98\#R[ZZ:5BQ3,\@JU?5&PH&U=>UF_C$C$1+
M%$D/I;#6,1;!C3\*?+&3&8E@"..0)Z&9D)]I?]R).B.H7!+#19:--&Q=-2P-
MJNJP/"(8,SL#0<,2)2)1#%SQ+8AF)^11,2)B!P0QMU%A7:>S-_#/]1+*+ "9
MM4;.->0-2MZB92MB+DR2F@4>[$L&8;6?8K&I[,K96NZSMFBV37-R08<K%K@X
M'&$ +)8*B85%3(8E8Q!L=5)!SXMSZT=KYO#245QUKZD=U2X[SS3DY#V5G+>K
MAY%ER'FL&AOM,?$M@D!1M/R(9VGWCWB)ZK&1Q];*T;&/M^::UH(6Z*]FQ4=Q
M@A/X+-5B;"IW&-R6P9F-QF9$IB8YVIK[=5IV7H:R:UW4G6^OJ%8[ 0W%07*@
M-L:]O@IXV%&"!DG)[F)E<4(DQR&<R(GR4_DQ@BI2I8:"T\JMU[KK-!M:[%:N
MAK"N5_"+/6+(1@ @YF)5PF"]Q^?/E\P&)ONGLQI;'8'5U#.:6+.9G+T:*-,9
MB,G8I?HU;0]IVK4U51(7_5+-/PNGX?2^&-EVG&*5W+4M,,R>]-]6S;^Q>T]%
M6ZK3*&=XTK3N;4!HMQTVS"1:Z?3H@NS+S#OK9\.AUN&%&5,Z#)S),TA(/FL#
MB,9IJ!M<M/C1N8.&0FLVTV5+*;>20V):F!&( YWV$E'#"F) "5*^.TTSM'4R
MZ>[ :CTWW,G&6+^;I8:B^]<4&"T;D:QA0OML-([-=8A!-7=0RHH"4]Z;L6!;
M)CE4_4E/ 'N$-^5C<FP^.=&UVC#-:UKBNS._I6O7:Z[?&E':G4;; )V9/W>Q
MVRIA:Y XJ+M5@,F <.7 FABJ"4V9ZP3D#I\J%/""N&UTVUDQ9>KQM=4 Q@&,
M09# [EY3E@_$PY;SF8B-?=6IEG=V3U)J/N5.3?4S61P=PZ=Q;,%K+*66/ITK
M-5PG70T6P"_0(748'AK5ETAK J9-R-4Z\W35[]OHYM#=6-F46_VT:4T_2F:D
M/J[NH:NP/F1R5=_-C'<3K Y-=?@(3-DJ0ZTH/^40M$XU/:84U*]U-F\VS=]4
MA[@.FCP@OT:A&8)<E&\MY3(^Y?XG+YF41=]29C2N3PNDJ."TL6!RN)QEBKJ?
M*_>EF[^DEYK5DFZ-=L"%#Q +BX)G_O7@C\.HDSDO6^O:UJFBUC7-/07;K%0%
MM!PJ#UB/6PNF$RM:T)GV*SD2QXJ]A3BO:02(RGDH^#*%I9::;0T>]EES'MX^
M1I29\ !8\I^?%:Q$!C^01B/KU0L=CZV*HUL=4\T5JBH2F+%A]MT ,S,>2S:8
MU[2]Y^)K"+;:(G:(B-V]:NIO1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1UK5
MNIE/OX*95KW5*U=:P1PE)"N6X$+L@*>E&?="9@@S%FCY6$YSG*</QUX3G/OC
MVSZV+:U)PQ+&*9'R-9D!Q_,0S!1_HGJ-;IT[Z#JWJM:[69[,KVT*LH9$?*#2
MX#66W^4,]17KKECF/4!I5DU/SMHW6=B5AQ.3]!U/1*@:PAU*D.-I*@ ,">AI
M:%*0II#Z6\I4I/Q]E*QF0_(W[0>.S>MV%^WP.LN:'M\IXF9#O'TG;I7CM+Z9
MP[IL8G3V#QEB=XE]#%4:;MB]ICRUT+9M,>TQRVV]MNI;L-8 VR'#'V(9'*PQ
MYZN6>%'D_4PB.>J)T?9JV3;RTMM7W D\*'DHWNK+>7XK:7D.-96VI>Q2W"(M
M"#$6*:,3O[,2P6J.-MO<& )1]-X]]XWCJTTK]S'-:ZC8.NUU.]0:8<=SIY*F
M^A>KER@HX6:=AR#]N4 R9&1*(*-5EZAUK.DKES*@+D2%W U?UNN?<YRJXV.B
ME-9FSV<8D83F82HAHK6I"?C]OF!->REE,CX/IU34K%.\I"9\QOW]_P"&8@ZS
M&?/\Q(,US].)3[;^_3!>I,ZD(6K)V ",95P\",AM&,I9>OGJE/\ )OXD9>I7
MOK]^<.4.Y2&X3J]>YPTS60HFN0*>X0 @IDN:%#VJS6Z\#Q2Y]+-ZZFQ1\6Z'
MS[405*I%C.5M\(RE =P<2D(5!RY\'$:EXVDH 4*>2UR1 #6->(<D'6*!AS&1
M 2AAJD(^#B4_#O[]3[NM]3W[5F\[)"FY<4M5JSCZ&-Q+[$)RE7-J8YF+ITR9
M97E:-2\%LIFT+T!,.X\AG(8YVTC'3#^.MJT_)'2-?RAQ2='>(G8#^K$5]&OU
MPK 0?DG(B:QFKA'H+<<@VTY+C/S):),LD3>F9C'48V_>RID9KD)E$DP9JPN*
M\BPIDQ\7B"1V*(Y1)3N1')>#UKJIDMWSEX5O#,K=748HIN#4,W9S,-I)!=1G
MKXR%H'2:9*%F"ER"T5P5^F8TEJ\[0!^KY]6;;HXD@-+"0XHL= O"B@<PD^,(
MBS(,H..CIT(PG$]B5#)L/)=]\?/+:E(SZ.C597&J2OP (3 !-@2! ?D A,#%
M@D)_%$P43O\ R=:*NJL_3S#L^G(3.6LI?6LV;%:G;&Q7LU9IV$6*MNN^H]3:
ML^$UM08R.T[<HB>OQ)/.&F9QJH6(C3E%3E'BUZ$")E[);2\IZ/4#DJST]-E6
M2/2L79=/LTV98JB_=,6!^KGI4@P!<'D7G)*O$XVD1I82>9HA<+(V-.9A)RU/
MEY,GS^%LRQ,O\DJ9,FN1*9GJ4O6^IU5<G21DHKU,LRZVXBM0QM98GDJBZ&3F
MC"*:_NJ,G04JEDAQ<TPR%-85;@N0,+C=9>L:%.6=<EUD>^Y9KY4]G'E+S(]R
M=]HL>EQ:E9I'Q?Q[$ <?7=*9B8;^G'RBO0L/L.^\CZV\JM<O)R4,^5Z;3-]_
MBL(A$);/O^9<5D1&VT?ACO$^^ZM>>S"HIBN^X(H8C(X&G$<-J^'RYY5F2H!N
M$_@VSS>5)G+<^5UL@8_!QT-GF?2$9=N5%HZ(:+MF4LW&A6"UPX,9Z=8XUPGR
MJL/BG6H-%FS[="AVJ?.I$>O3)UEB13LI]XK'9EHCQC*,2Z81MY]^<0QL#$DR
M'%*AAD"@B<(M(D0LB8,,F9.(GIN6N]5G&-AF5ELXJ%Q58VECFN8"J3,8E>0<
MRH3LNE.-:W')3ECNJ508RFL!KF2YDZETJL:\K0^HTX4@-7QKA&1&AIDS9SSD
MTR4FG#1*>1)29A,J7-&R1$R:+E)DPF7+3YI(C+DS93[[DI"%5E"E(0"QDI@=
MR*>1F3#(B*2(S,R(S,B(C,B(IDIF90Y3*W\U>=DLG8FU<>* -LK4H155KJJ5
M4)0@%5Z]:K40BK5K5U*KUJR5(0M:E@$;3ZV]+^CT='4,:4_U=L7_ (S[3_\
MM,KU+M_FK_U2M_NXZ3X;^#R'^>,I_:SZ]W/_ -6UG_QFUS_\JYZQ5^;_ .JO
M_P!CHS'Y<;_GC'?[V>IF]1>G'1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>
JCHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
